Trial Results Support Adding Daratumumab to Initial Treatment for Multiple Myeloma - Cancer Currents Blog

National Cancer Institute sent this bulletin at 01/22/2024 10:51 AM EST

Having trouble viewing this email? View it as a Web page.

Trial Results Support Adding Daratumumab to Initial Treatment for Multiple Myeloma
01/19/2024
	Adding daratumumab (Darzalex) to standard treatment helped people with newly diagnosed multiple myeloma live longer without their cancer getting worse or dying. People taking daratumumab were also more likely to have no detectable signs of cancer (minimal residual disease) after treatment.

You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.